Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.

ABSTRACT:

Background

Cannabis use is frequent in Parkinson's disease (PD), despite inadequate evidence of benefits and risks.

Objective

The aim is to study short-term efficacy and tolerability of relatively high cannabidiol (CBD)/low Δ-9-tetrahydrocannabinol (THC) to provide preliminary data for a longer trial.

Methods

Persons with PD with ≥20 on motor Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) who had negative cannabis testing took cannabis extract (National Institute of Drug Abuse) oral sesame oil solution for 2 weeks, increasing to final dose of 2.5 mg/kg/day. Primary outcome was change in motor MDS-UPDRS from baseline to final dose.

Results

Participants were randomized to CBD/THC (n = 31) or placebo (n = 30). Mean final dose (CBD/T

SUBMITTER: Liu Y 

PROVIDER: S-EPMC11102313 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature